放线菌素D，现配溶液

<ul>
<li><strong>Regulation of Immune Checkpoints in Cancer:</strong> Actinomycin D is pivotal in studying the ADAR-mediated RNA editing processes that regulate PVR immune checkpoints in colorectal cancer, thus demonstrating its crucial role in cancer immunotherapy research and providing insights into novel therapeutic targets (Qian et al., 2024).</li>
<li><strong>Chemotherapy and Immunotherapy Combination:</strong> The use of Actinomycin D in combined chemotherapy highlights its effectiveness in salvaging multi-chemotherapy agent and avelumab resistant choriocarcinoma, showcasing its potential in overcoming resistance to treatment in gynecological cancers (Lehmann et al., 2023).</li>
<li><strong>Advancements in Dental Medicine:</strong> Actinomycin D is used in regulating gene expression crucial for tissue regeneration and repair in dental health and it is also used to determine RNA stability assay (Pan et al., 2023).</li>
<li><strong>Cancer Progression Research:</strong> The study on hypoxia-induced lncRNA in hepatocellular carcinoma progression, where RNA-binding proteins play a critical role, aligns with Actinomycin D′s application in transcriptional inhibition and its influence on mRNA stability, essential for understanding cancer biology and developing targeted therapies (Tuo et al., 2023).</li>
</ul>

放线菌素D是一种抑制细胞增殖的抗肿瘤抗生素。它是抗肿瘤细胞凋亡的细胞毒性诱导剂。该化合物通过与双链DNA形成稳定的复合物（通过脱氧鸟苷残基）以非特异性方式抑制细胞增殖，从而抑制DNA引发的RNA合成。它还会导致DNA的单链断裂。

放线菌素D已被证明是逆转录中负链转移步骤的抑制剂，因此可用于研究和抑制HIV复制。还显示它可以抑制依托泊苷（拓扑异构酶II的抑制剂）诱导的PC12细胞程序性细胞死亡。

在细胞培养中，放线菌素D用作选择剂。已经研究了放线菌素D与核糖体RNA中酵母的结合。研究了各种大肠埃希菌菌株对放线菌素D的敏感性和结合机理。放线菌素D在分子生物学中也用作阻断RNA聚合酶进展的DNA嵌入剂。

1ML

放线菌素D溶液对光非常敏感。

使用前，可将2 mg/mL溶液在适当的缓冲液中进一步稀释。